NAD+ / MOTS-c / 5-Amino-1MQBlend

NAD+ + MOTS-c + 5-Amino-1MQ metabolic & longevity blend.

Peptides·Index rating

1/5Speculative

Human data

Safety

Compare prices — from $60.00

Quick factsat a glance

Status: Research / not approved
Developer: Compounded research blend; vendor-specific
Receptors / target: Not a single target — combines NAD+ (redox coenzyme), MOTS-c (mitochondrial-derived peptide) and 5-Amino-1MQ (NNMT inhibitor); all converge on cellular and mitochondrial energy metabolism
FDA-approved?: NO
Prescription available?: NO
Studied for: cellular & mitochondrial metabolismNAD+ / energy metabolismmetabolic regulation / insulin sensitivityaging / longevity research

Overview

NAD+ / MOTS-c / 5-Amino-1MQ is a compounded metabolic / longevity research blend combining three agents that converge on cellular and mitochondrial energy metabolism: the redox coenzyme NAD+, the mitochondrial-derived peptide MOTS-c, and the NNMT inhibitor 5-Amino-1MQ (which is a small molecule, not a peptide). It is sold research-use-only, is not an approved drug, and has no clinical trials as a combination.

Mechanism

The three converge on energy metabolism by different routes. NAD+ is an essential redox coenzyme and substrate for sirtuins/PARPs/CD38. MOTS-c is a mitochondrial-derived peptide that activates AMPK and promotes metabolic homeostasis. 5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), which is proposed to raise cellular NAD+ and SAM. The blend's rationale is converging support of the NAD+/mitochondrial axis, but the combined pharmacology has not been characterized, and the MOTS-c and 5-Amino-1MQ mechanisms are established only in cell and animal models.

Clinical evidence

There are no trials of this blend. Per component, the evidence is uneven: human RCTs exist for NAD+ precursors (nicotinamide riboside/NMN raise NAD+ but with limited proven clinical benefit, and IV NAD+ itself has only pilot data), while MOTS-c and 5-Amino-1MQ are preclinical-only with no human interventional trials. No controlled human evidence supports the combination for anti-aging, energy or metabolic outcomes; such claims should be treated as unproven.

Safety profile

The combined safety has not been studied. The most concrete acute issue is rapid IV NAD+, which commonly causes flushing, nausea and chest/abdominal tightness (mitigated by slowing the infusion); injection-site reactions apply to the subcutaneous components. Human safety of MOTS-c and 5-Amino-1MQ is essentially unstudied, and research-grade purity is unverified. None are FDA-approved, and the blend is not WADA-listed (though a high-volume IV NAD+ infusion is itself a banned method). Research-use only; nothing here is therapeutic or dosing guidance.

Timelinecommonly reported

During IV / per dose
IV NAD+ is infused slowly over hours (rapid infusion causes flushing). MOTS-c and 5-Amino-1MQ have no human time-course.
Weeks
No trials of the blend exist; NAD+ precursors raise NAD+ over weeks without proven benefit, and the peptide/small-molecule components are preclinical. Any timeline is unverified.

Reported side effectsreported in literature

Reported in published literature and user reports. Not a complete list, and not medical advice.

Flushing, nausea, chest/abdominal tightness with rapid IV NAD+
Injection-site reactions
Human safety of MOTS-c and 5-Amino-1MQ is essentially unstudied
Unstudied combined safety

If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.

Cautionsdiscuss with a clinician

Use caution or avoid if

No human safety data exist for the combination; it is unstudied and research-use only.
Rapid IV NAD+ commonly causes flushing, nausea and chest/abdominal tightness — infusions should be given slowly; this is the most concrete acute risk.
Human safety of MOTS-c and 5-Amino-1MQ is essentially unstudied, and research-grade purity is unverified.

Interactions

No documented human drug interactionsNo interaction studies of the combination; uncharacterized in humans (research use only)

Compare

vs NAD+
The single NAD+ component, the most-studied of the three.
vs MOTS-c
The single mitochondrial-derived-peptide component (preclinical-only).
vs 5-Amino-1MQ
The single NNMT-inhibitor component (a small molecule, preclinical-only).

FAQ

Is the NAD+/MOTS-c/5-Amino-1MQ blend studied in clinical trials?

No. There are no trials of this blend. Per component, human RCTs exist for NAD+ precursors (with limited proven clinical benefit), while MOTS-c and 5-Amino-1MQ are preclinical-only with no human interventional trials. Combined benefit is unproven.

What is in this blend?

Three agents that converge on cellular and mitochondrial energy metabolism — the redox coenzyme NAD+, the mitochondrial-derived peptide MOTS-c, and the NNMT inhibitor 5-Amino-1MQ (a small molecule, not a peptide).

Is it banned in sport?

The blend is not on the WADA Prohibited List, though a high-volume IV NAD+ infusion can itself fall under the prohibited-method rules on IV infusions.

Why combine NAD+, MOTS-c and 5-Amino-1MQ?

All three are proposed to support the NAD+/mitochondrial energy axis by different routes — NAD+ as a direct redox coenzyme, MOTS-c by activating AMPK, and 5-Amino-1MQ by inhibiting NNMT (which is proposed to raise cellular NAD+). The rationale is converging metabolic support, but the combined pharmacology has not been characterized and the MOTS-c and 5-Amino-1MQ mechanisms are established only in cell and animal models.

Why is rapid IV NAD+ a safety concern?

Infused too quickly, IV NAD+ commonly causes flushing, nausea and chest or abdominal tightness; this is the most concrete acute risk of the blend and is mitigated by slowing the infusion (NAD+ is typically given over hours). The subcutaneous components carry injection-site reactions, and the combined safety is otherwise unstudied. Research use only.

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide — so this is a mixed peptide/small-molecule blend rather than a pure peptide stack. Its activity is established only in animal models, with no human interventional trials, and research-grade purity is unverified.

Similar compounds

NAD+LongevityCoenzyme studied for cellular energy and longevity.MOTS-cLongevityMitochondrial peptide studied for metabolism and endurance.5-Amino-1MQWeight Loss / GLP-1NNMT inhibitor studied for fat metabolism and energy.

Sources

Starting references for the library summary. These are not dosing instructions or medical advice.

NAD+ metabolism and its roles in cellular processes during ageingNature Reviews Molecular Cell Biologypubmed.ncbi.nlm.nih.gov/33353981/…Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adultsNature Communicationspubmed.ncbi.nlm.nih.gov/29599478/…The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceCell Metabolismpubmed.ncbi.nlm.nih.gov/25738459/…Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in miceBiochemical Pharmacologypubmed.ncbi.nlm.nih.gov/29155147/…

For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.